| Título: | Prevalence and Predictors of Potential Drug-Drug Interactions in the Elderly: A Cross-Sectional Study in the Brazilian Primary Public Health System |
| Autores: |
Obreli Neto, Paulo Roque; Department of Pharmacology and Therapeutics, State University of Maringá, Maringá, PR, Brazil Nobili, Alessandro; Laboratory of Quality Assessment of Geriatric Therapies and Services, and Drug Information Services for the Elderly, Istituto di Ricerche Farmacologiche, Milano, Italy. Marusic, Srecko; Department of Clinical Pharmacology, University Hospital Dubrava, Zagreb, Croatia. Pilger, Diogo; Department of Medicines, Federal University of Bahia, Salvador, BA, Brazil. Guidoni, Camilo Molino; Department of Pharmaceutical Sciences, University of São Paulo, Ribeirão Preto, SP, Brazil. Baldoni, André de Oliveira; Department of Pharmaceutical Sciences, University of São Paulo, Ribeirão Preto, SP, Brazil. Cruciol-Souza, Joice Mara; Department of Pharmaceutical Sciences, State University of Londrina, Londrina, PR, Brazil. da Cruz, Alessandra Negri; Department of Pharmacy, Faculdades Integradas de Ourinhos, Ourinhos, SP, Brazil. Gaeti, Walderez Penteado; Department of Pharmacology and Therapeutics, State University of Maringá, Maringá, PR, Brazil. Cuman, Roberto Kenji Nakamura; Department of Pharmacology and Therapeutics, State University of Maringá, Maringá, PR, Brazil. |
| Fecha: | 2012-05-04 |
| Publicador: | Journal of Pharmacy and Pharmaceutical Sciences |
| Fuente: |
 |
| Tipo: |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| Tema: | No aplica |
| Descripción: | Purpose. The primary objective of this study was to investigate the prevalence of clinically important potential drug-drug interactions (DDIs) in elderly patients attending the public primary health care system in Brazil. The secondary objective was to investigate possible predictors of potential DDIs. Methods. A cross-sectional study was carried out in 5 Brazilian cities located in the Ourinhos Micro-region, Sao Paulo State, between November 2010 and April 2011. The selected sample was divided according to the presence (exposed) or absence (unexposed) of one or more potential DDIs (defined as the presence of a minimum 5-day overlap in supply of an interacting drug pair). Data were collected from medical prescriptions and patients’ medical records. Potential DDIs (rated major or moderate) were identified using 4 DDI-checker programs. Logistic regression analysis was used to study potential DDI predictors. Results. The prevalence of clinically important potential DDIs found during the study period was 47.4%. Female sex (OR = 2.49 [95% CI 2.29–2.75]), diagnosis of ≥ 3 diseases (OR = 6.43 [95% CI 3.25–12.44]), and diagnosis of hypertension (OR = 1.68 [95% CI 1.23–2.41]) were associated with potential DDIs. The adjusted OR increased from 0.90 [95% CI 0.82–1.03] in patients aged 60 – 64 years to 4.03 [95% CI 3.79 – 4.28] in those aged 75 years or older. Drug therapy regimens involving ≥ 2 prescribers (OR = 1.39 [95% CI 1.17–1.67]), ≥ 3 drugs (OR = 3.21 [95% CI 2.78–3.59]), ≥ 2 ATC codes (OR = 1.19 [95% CI 1.12–1.29]), ≥ 2 drugs acting on cytochrome P450 (OR = 2.24 [95% CI 2.07–2.46]), and ATC codes B (OR = 1.89 [95% CI 1.05–2.08]) and C (OR = 4.01 [95% CI 3.55–4.57]) were associated with potential DDIs. Conclusion. Special care should be taken with the prescription and therapeutic follow-up of patients who present characteristics identified as predictors. Knowledge of potential DDI predictors could aid in developing preventive practices and policies that allow public health services to better manage this situation. This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page. |
| Idioma: | Inglés |
1 The Impact of Electronic Prescribing on the Professionalization of Community Pharmacists: A Qualitative Study of Pharmacists’ Perception por Motulsky, Aude; Université de Montréal,Winslade, Nancy; McGill University,Tamblyn, Robyn; McGill University,Sicotte, Claude; Université de Montréal | 6 Effect of Inflammation on Molecular Targets and Drug Transporters por Hanafy, Sherif; Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada,El-Kadi, Ayman O.S.,Jamali, Fakhreddin; Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada |
2 Statins Against Drug-Induced Nephrotoxicity por Dashti-Khavidaki, Simin; Tehran University of Medical Sciences,Moghaddas, Azadeh; Tehran University of Medical Sciences,,Heydari, Behrooz; Tehran University of Medical Sciences,,Khalili, Hossein; Tehran University of Medical Sciences,lessan-Pezeshki, Mahboob; Tehran University of Medical Sciences,,Lessan-Pezeshki, Mahbooh; Tehran University of Medical Sciences | 7 |
3 Hepatotoxic Botanicals - An Evidence-based Systematic Review por Abdualmjid, Reem J; University of Alberta,Sergi, Consolato; University of Alberta | 8 |
4 The Decrease in Farnesoid X Receptor, Pregnane X Receptor and Constitutive Androstane Receptor in the Liver after Intestinal Ischemia-Reperfusion por Ogura, Jiro,Terada, Yusuke,Tsujimoto, Takashi,Koizumi, Takahiro,Kuwayama, Kaori,Maruyama, Hajime,Fujikawa, Asuka,Takaya, Atsushi,Kobayashi, Masaki,Itagaki, Shirou,Takahashi, Natsuko,Hirano, Takeshi,Yamaguchi, Hiroaki,Iseki, Ken | 9 Functional Food and Nutraceutical Registration Processes in Japan and China: A Diffusion of Innovation Perspective por Patel, Darshika; University of Auckland,Dufour, Yvon; University of Auckland,Domigan, Neil; Auctus Limited |
5 HPLC Analysis of Mesembrine-Type Alkaloids in Sceletium Plant Material Used as An African Traditional Medicine por Patnala, Srinivas; Rhodes University,Kanfer, Isadore; Faculty of Pharmacy, Rhodes University | 10 Inhibition of Human Cytochrome P450 Metabolism by Blended Herbal Products and Vitamins por Tam, Teresa W; Centre for Research in Biopharmaceuticals and Biotechnology, University of Ottawa, Ottawa, ON,Akhtar, Humayoun; Guelph Food Research Centre, Agriculture and Agri-Food Canada, Guelph, ON,Arnason, John Thor; Centre for Research in Biopharmaceuticals and Biotechnology, University of Ottawa, Ottawa, ON,Cvijovic, Kosta; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON,Boon, Heather; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON,Cameron, D William; Faculty of Medicine, Univeristy of Ottawa, Ottawa, ON,Drouin, Cathy E; Centre for Research in Biopharmaceuticals and Biotechnology, University of Ottawa, Ottawa, ON,Jaeger, Walter; Department of Clinical Pharmacy and Diagnostics, University of Vienna, Vienna,Tsuyuki, Ross T; Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB,Vohra, Sunita; CARE Program, Faculty of Medicine and School of Public Health, University of Alberta, Edmonton, AB,Foster, Brian C; Office of Science, Therapeutic Products Directorate, Health Canada, Ottawa, ON |